recoveryELISA TNFalpha Neutralization Rate/Adalimumab Kit (RTA), IvD, CE certified

The unique recoveryELISA technology monitors parallel the free drug Adalimumab, the free antigen TNF alpha concentration and the neutralization rate of TNF alpha in patient sera during Adalimumab therapy. This next generation therapeutic drug monitoring tool can be used by diagnostic laboratories and medical doctors for research to find a personalized medication dose for each patient individually.

Adalimumab: 0.7 – 30 ug/mL; TNF alpha in sample without Adalimumab: 4-400ng/ml; TNF alpha in sample with Adalimumab: 4-160ng/ml

Therapies and studies with adalimumab

1. Strohner P: Patent: EP 1957980B1
Immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a treatment antibody targeting the analyte in samples (Recovery immunoassay)

2. Korn S, Haasler I, Jung M, Strohner P, Staatz A, Schäfer A, Becher G, Taube C and Buhl R
Free serum IgE in patients with severe allergic asthma treated with Omalizumab
Am. J. Respir. Crit. Care Med., May 2010; 181: A6655

3. Strohner P, Sarrach D, Reich JG, Becher G, Staatz A, Schäfer A, Steiß J-O, Häupl T:
The Recovery-ELISA – a novel Assay Technique for the Therapy Control of Therapeutic Antibodies
Am J Respir Crit Care Med 181; 2010:A5674

4. Strohner P, Staatz A, Schäfer A, Becher G, Sarrach D, Reich JG, Steiß J-O, Häupl T:
Monitoring of Monoclonal Antibody Therapy with a new Recovery ELISA Assay Technique (R-ELISA)
ERS Barcelona 2010, Abstract-No: 3399

5. Steiß JO, Schmidt A, Lindemann H, Rudloff S, Staatz A, Strohner P, Becher G, Nährlich L, Zimmer KP: Therapiemonitoring von Omalizumab im Kindes- und Jugendalter. Allergologie, Jahrgang 33, Nr. 10/2010, S. 421–428

Adalimumab and free TNF alpha

Adalimumab and free TNF alpha

ice pack to temperature >25C

2-8'C

microplate, buffers, antibody conjugate, standards

human serum